News Release

Research Article Cites HemogloBind™ in Diabetic Complications Study

MONMOUTH JUNCTION, NJ, May 23, 2018 -- Biotech Support Group reports on a recent research article describing the describing the simplicity and efficiency of their hemoglobin depletion technology for improving Western blot analysis from whole blood. The citation is:  

Pácal, Lukáš, et al. "Deleterious Effect of Advanced CKD on Glyoxalase System Activity not Limited to Diabetes Aetiology." International Journal of Molecular Sciences 19.5 (2018): 1517.

The authors studied Methylglyoxal production known to increase in diabetic patients. Methylglyoxal is efficiently detoxified by enzyme glyoxalase 1 (GLO1). The aim was to study the effect of diabetic and chronic kidney disease milieu on (a) GLO1 gene expression in peripheral blood mononuclear cells; (b) GLO1 protein levels in whole blood; and (c) GLO1 activity in RBCs in vivo in diabetic vs. non-diabetic subjects with normal or slightly reduced vs. considerably reduced renal function (CKD1-2 vs. CKD3-4). To evaluate the GLO1 protein levels in whole blood by Western blot, the article states “For protein isolation, whole blood aliquots were lysed with water and haemoglobin was removed using HemogloBind™ (Biotech Support Group, Monmouth Junction, NJ, USA) according to the manufacturer’s instructions…”. The article concludes that chronic kidney disease in advanced stages has prevailing and suppressive effects compared to hyperglycaemia. Chronic kidney disease decreases GLO1 gene expression and protein levels (together with diabetes) without concomitant changes of GLO1 activity.

“The large amount of hemoglobin in whole blood presents a special challenge for quantitative Western blot analysis. Here is another article demonstrating that HemogloBind™ can reduce the interference associated with large concentrations of hemoglobin, without compromising the recovery and analysis of the protein of interest.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemogloBind™, visit:

http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com